PHARMING GRP SP. ADRS - Asset Resilience Ratio
PHARMING GRP SP. ADRS (PHG) has an Asset Resilience Ratio of 6.76% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PHARMING GRP SP. ADRS current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how PHARMING GRP SP. ADRS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PHG current and non-current assets.
Liquid Assets Composition Over Time
This chart breaks down PHARMING GRP SP. ADRS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore PHARMING GRP SP. ADRS strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €33.80 Million | 6.76% |
| Total Liquid Assets | €33.80 Million | 6.76% |
Asset Resilience Insights
- Limited Liquidity: PHARMING GRP SP. ADRS maintains only 6.76% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
PHARMING GRP SP. ADRS Industry Peers by Asset Resilience Ratio
Compare PHARMING GRP SP. ADRS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for PHARMING GRP SP. ADRS (2022–2025)
The table below shows the annual Asset Resilience Ratio data for PHARMING GRP SP. ADRS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.76% | €33.80 Million ≈ $39.51 Million |
€499.96 Million ≈ $584.51 Million |
-21.48pp |
| 2024-12-31 | 28.24% | €112.95 Million ≈ $132.05 Million |
€399.99 Million ≈ $467.62 Million |
-4.53pp |
| 2023-12-31 | 32.77% | €151.68 Million ≈ $177.33 Million |
€462.85 Million ≈ $541.12 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€425.80 Million ≈ $497.80 Million |
-- |
About PHARMING GRP SP. ADRS
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more